

NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ARTICLE ON NEW DRUG FOR TREATMENT OF PAGET'S DISEASE

A head to head study published September 1, 2005 in The New England Journal of Medicine (353:898-908) reports that a single infusion of the bisphosphonate drug zoledronic acid (5 mg solution) offers superior efficacy, a longer period of remission and a faster onset of action compared to the drug Actonel[®].

The lead author of the study, Dr. Ian Reid of the University of Auckland, New Zealand, states "This study may provide a new and effective option for the management of Paget's disease by showing that a single dose of 5 mg zoledronic acid is more effective than the current standard of care (Actonel[®])."

Zoledronic acid 5mg solution (Aclasta[®]) has received approval for the treatment of Paget's disease in many countries. The drug has not received approval by the U.S. Food and Drug Administration (FDA), but has received an "approvable letter" from the FDA.

To read the article use the following link:

<http://content.nejm.org/cgi/content/abstract/353/9/898>